Evidence map›Paper›PMID 32948241›Full record

ArticleJournal of ovarian research2020

microRNA-1271-5p/TIAM1 suppresses the progression of ovarian cancer through inactivating Notch signaling pathway.

Feng-Juan Han, Jia Li, Ying Shen, Ying Guo, Yi-Chao Liu, Yang Yu, Jia-Yue Xu, Shao-Xuan Liu, Yan-Hong Wang

Open access · goldAbstract read
In one paragraph

Article in Journal of ovarian research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Metastasis and cancer associated fibroblasts: taking it up a NOTCH.Frontiers in cell and developmental biology · 2023
    Review
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Feng-Juan HanDepartment of Gynecology, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Jia LiHeilongjiang University of Traditional Chinese Medicine, First Clinical Medical College, Harbin, 150040, Heilongjiang, China.
Ying ShenHeilongjiang University of Traditional Chinese Medicine, First Clinical Medical College, Harbin, 150040, Heilongjiang, China.
Ying GuoDepartment of Gynecology, The First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Yi-Chao LiuDepartment of Chinese medicine, Harbin Institute of Technology Hospital, Harbin, 150006, Heilongjiang, China.
Yang YuHeilongjiang University of Traditional Chinese Medicine, First Clinical Medical College, Harbin, 150040, Heilongjiang, China.
Jia-Yue XuHeilongjiang University of Traditional Chinese Medicine, First Clinical Medical College, Harbin, 150040, Heilongjiang, China.
Shao-Xuan LiuHeilongjiang University of Traditional Chinese Medicine, First Clinical Medical College, Harbin, 150040, Heilongjiang, China.
Yan-Hong WangHeilongjiang University of Traditional Chinese Medicine, College of Pharmacy, No. 24, Heping Road, Xiangfang District, Harbin, 150040, Heilongjiang Province, China. hljzyylj@163.com.ORCID http://orcid.org/0000-0002-2241-5237
Heilongjiang University · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CNHarbin Institute of Technology · CNHeilongjiang University of Chinese Medicine · CN

Funding

Heilongjiang Provincial Science Fund Project ZD2018020Heilongjiang University of Traditional Chinese Medicine Graduate Innovation Research Project 2019yjscx007
6 · The paper itself

Abstract

objectiveOvarian cancer (OC) has been regarded as the most malignant gynecological neoplasm and often confers grave outcomes owing to the frequent metastasis and high recurrence. A previous study has demonstrated that miR-1271-5p is implicated in OC progression, however, the possible mechanism of it remains unknown. The purpose of this investigation was to explore how miR-1271-5p regulates the progression of OC.

methodsGene Expression Omnibus (GEO) and The Cancer Genome Atlas (TCGA) databases were employed to analyze the differentially expressed miRNAs or genes as well as their corresponding prognostic values. miR-1271-5p expression in OC cells was examined by qRT-PCR. Cell counting kit 8 (CCK-8), colony formation, and transwell tests were conducted to evaluate the proliferation, migration and invasion potentials. Bioinformatics prediction and luciferase activity analysis were utilized to predict and verify the target gene of miR-1271-5p. Western blot assay was carried out to measure protein expression.

resultsmiR-1271-5p was significantly decreased in OC and its down-regulation was associated with the grave outcome of OC patients. Upregulation of miR-1271-5p inhibited cell viability, but miR-1271-5p knockdown promoted the proliferation of OC cells. TIAM1 was a direct target gene of miR-1271-5p and expressed in OC tissues at higher level. High expression of TIAM1 induced the poorer prognosis of patients with OC. Further functional analyses showed that the suppressive role of miR-1271-5p on OC cell malignant behaviors was overturned by the upregulation of TIAM1. The protein levels of Cyclin D1, HES1, NOTCH and NUMB were remarkably changed due to the abnormal expression of miR-1271-5p and TIAM1.

conclusionTo sum up, miR-1271-5p inhibits proliferation, invasion and migration of OC cells by directly repressing TIAM1 to inactivate the Notch signaling pathway, which provides an alternative therapeutic candidate for the advancement of OC treatment.

Indexed as

Disease ProgressionFemaleHumansMicroRNAsOvarian NeoplasmsPrognosisSignal TransductionT-Lymphoma Invasion and Metastasis-inducing Protein 1TransfectionMicroRNAsMIRN1271 microRNA, humanTIAM1 protein, humanT-Lymphoma Invasion and Metastasis-inducing Protein 1Cell behaviormiR-1271-5pNotch pathwayOvarian cancerPrognosis

Identifiers

PMID32948241
PMCPMC7501628
OpenAlexW3087000744

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.